Compare Stocks

EMX Royalty Corporation, together with its subsidiaries, explores for and generates royalties from metals and minerals properties. It explores for gold, silver, platinum, palladium, copper, lead, zinc, nickel, cobalt, volcanogenic massive sulfide, molybdenum, and iron deposits. The company's royalty and exploration portfolio primarily consist of properties in North America, Turkey, Europe, Australia, and Latin America. The company was formerly known as Eurasian Minerals Inc. and changed its name to EMX Royalty Corporation in July 2017. EMX Royalty Corporation is headquartered in Vancouver, Canada.

Minco Silver Corporation, an exploration stage company, engages in exploring, evaluating, and developing precious metals mineral properties and projects. The company explores for gold and silver deposits. It holds interests in the Fuwan Silver project. Minco Silver Corporation was incorporated in 2004 and is headquartered in Vancouver, Canada.

Nuveen Massachusetts Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of Massachusetts, United States. The fund primarily invests in undervalued municipal securities and other related investments which are exempt from regular federal and Massachusetts income taxes. It seeks to invest in investment grade securities that are rated Baa/BBB or above by S&P, Moody's, or Fitch. The fund employs fundamental analysis with a focus on bottom-up stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against the Standard & Poor's (S&P) Massachusetts Municipal Bond Index and Standard & Poor's (S&P) National Municipal Bond Index. The fund was formerly known as Nuveen Massachusetts Premium Income Municipal Fund. Nuveen Massachusetts Quality Municipal Income Fund was formed on January 12, 1993 and is domiciled in the United States.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.